Rationale: Although several functional studies have demonstrated that positron emission tomography/computed tomography with 18 F-fluorodeoxyglucose ( 18 F-FDG PET/CT) appears to be efficient to identify a cerebral substrate in patients with known macrophagic myofasciitis (MMF), the predictive value of this imaging technique for MMF remains unclear.
Introduction
Macrophagic myofasciitis (MMF) is an unusual inflammatory myopathy characterized by specific muscle lesions. Lesions are assessing abnormal long-term persistence of aluminum hydroxide within macrophages at the site of previous vaccine injection containing aluminum hydroxide adjuvant particles. Evolution of this chronic disease is slow and symptoms (which typically include arthromyalgias, chronic fatigue, and a cognitive dysfunction) first may occur from months or years after the last vaccine injection. [1] [2] [3] [4] [5] Several positron emission tomography/ computed tomography with 18 F-fluorodeoxyglucose ( 18 FFDG PET/CT) studies have investigated these cognitive disorders. [6, 7] Although this imaging technique appears to be efficient to identify a cerebral substrate in patients with a known MMF, the predictive value of brain 18 F-FDG PET/CT to diagnose MMF remains unclear.
Case report
We presented the case of a 46-year-old woman which was referred to our center for suspected MMF due to chronic diffuse arthromyalgias, fatigue, and cognitive impairment which occurred at age 37, in the context of multiple aluminum hydroxide-based vaccines administration (hepatitis B vaccine at age 27, diphteria/tetanus/polio at age 32, 33, and 43). A first deltoid muscle biopsy was performed at age 45 and was normal showing no inflammatory lesion. In spite of this result, the clinical probability of MMF was high, neurocognitive tests showing an impairment of visual selective attention and a weakness in executive functions. Therefore, a brain 18 F-FDG PET/CT was performed as part of the work-up on a Gemini GXL instrument PET/CT scanner (Philips, Da Best, The Netherlands) after intravenous injection of 265 MBq of 18 F-FDG. Informed consent was obtained. The patient was required to fast for at least 6 hours before undergoing the scan, had a normal blood sugar level, and an update neurosensory rest for 30 minutes. A low-dose helical CT was first performed for anatomical correlation and attenuation correction with the following parameters: X-ray tube tension F-FDG PET is showed the known spatial pattern of a cerebral glucose hypometabolism involving occipital cortex, medial temporal areas, and cerebellum (white arrows). ). Visual analysis showed the known spatial pattern of a cerebral glucose hypometabolism involving occipital cortex, medial temporal areas, and cerebellum (Fig. 1) .
Given the clinical suspicion of MMF and brain 18 F-FDG PET/ CT findings, deltoid muscle biopsy was reiterated at age 46 and confirmed the diagnosis of MMF with typical histopathological features (Fig. 2) .
Discussion
It is now well established that 18 F-FDG PET imaging, which measures glucose consumption in neuron bodies, is a highly useful imaging modality for the diagnosis of neurodegenerative disorders, in particular for specific types of dementia such as frontotemporal dementia, Alzheimer disease, dementia with Lewy bodies and more recently in MMF each of which has characteristics metabolic patterns. [8, 9] In a large series of 100 patients, we described a peculiar spatial pattern of a cerebral glucose hypometabolism involving occipital lobes, temporal lobes, limbic system, cerebellum, and frontoparietal cortices and showed that MMF is a slowly progressive or nonprogressive disease, in accordance with the fact that neurologic symptomseven if they fluctuate -do not worsen or improve over time. [10, 11] The teaching point of this report is that brain 18 F-FDG PET/CT should be performed in patients with suspected MMF and cognitive impairment. The risk of false-negative muscle biopsy is known, due to the heterogeneous and focal distribution of inflammatory sites. [12] Then, in case of suspected MMF associated with suggestive brain 18 F-FDG PET pattern, muscle biopsy at site of vaccine injections may have to be repeated after an initial negative result. This case highlights the predictive value of the brain 18 F-FDG PET/CT for MMF. Brain 18 F-FDG PET/CT could be considered as a noninvasive imaging tool to diagnose MMF even when muscle biopsy result comes back negative. Further studies are warranted to validate our findings.
